Крупнейшее исследование с анализом костных биопсий при остеопорозе демонстрирует превосходное действиебивалоса® (стронция ранелата)на процессы формирования костной ткани по сравнению с бисфосфонатами

1. <div><p>Chavassieux P., Brixen K., Zerbini C. et al. Bone formation is significantly greater in women on strontium ranelate than in those on alendronate after 6 and 12 months of treatment: histomorphometric analysis from a large randomized controlled trial. Osteoporos Int 2011. Abstract OC16. Presented at the ECCEO Congress, Valencia, Spain, March 2011.</p><p>Ott S.M. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90: 1897-9.</p><p>Rizzoli R., Felsenberg D., Laroche M. et al. Beneficial effects of strontium ranelate compared to alendronate on bone microstucture - A 2 year study. Osteoporos Int 2010; 21(Suppl 1): S28-S29(Abstract P107).</p><p>Meunier P.J., Roux C., Seeman E. et al. The effects of strontium ranelate on the risk of non vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.</p><p>Reginster J.Y., Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 2005; 90(5): 2816-22.</p><p>Reginster J.Y., Felsenberg D. et al. Effect of long term strontium ranelate treatment on the risk of non vertebral and vertebral fractures in postmenopausal osteoporosis. Arthr Rheum 2008; 58(6): 1687-95.</p><p>Reginster J.Y., Kaufman J.M., Goemaere S. et al. Long-term treatment of postmenopausal osteoporotic women with strontium ranelate: results at 10 years. Osteoporos Int 2010; 21(Suppl. 5): S665-S666 (Abstract OC4).</p></div><br />